FDA Warns of Adverse Events Linked to Unapproved Compounded Versions of GLP-1 Drugs

The Food and Drug Administration has updated its safety communications regarding compounded semaglutide. Officials cite reports of patients experiencing nausea, vomiting, diarrhea, dehydration, abdominal pain, pancreatitis and gallbladder issues. Some of those cases resulted in hospitalization. These warnings matter because demand for the drug has led to widespread availability of unapproved versions.

The agency detailed these risks in a communication dated June 4, 2024. Compounded products often contain semaglutide salts instead of the base form found in approved drugs like Ozempic, Wegovy and Rybelsus. The FDA states these products have not been evaluated for safety, quality or efficacy. [3]

Semaglutide injection remains on the FDA shortage list. [1] This status allows compounding by certain pharmacies under sections 503A and 503B of federal law. The FDA says many marketed compounded products do not meet those requirements. Reports mention dosing errors along with contamination risks.

European regulators face comparable supply challenges. The EMA oversees approved semaglutide products and emphasizes the need for verified sources. [2] Both the FDA and EMA note that compounded drugs do not go through the same approval process as brand name versions.

What this means

Safety signals from voluntary reports reveal potential problems with products made outside regulated facilities. Use of unapproved salt forms and other impurities appears in some compounded supplies. These issues coincide with the period of high demand that exceeded approved production capacity. The data come from systems that capture only a portion of actual events.

Key takeaways

• Compounded semaglutide may contain different salt forms and impurities not present in approved products, according to FDA communications.
• The FDA has linked adverse events such as nausea, vomiting, diarrhea, dehydration, abdominal pain, pancreatitis and gallbladder issues to compounded versions, with some resulting in hospitalization.
• Semaglutide remains listed in shortage, permitting compounding only under sections 503A or 503B and only when approved drugs are unavailable.
• Approved products including Ozempic, Wegovy and Rybelsus have completed full FDA and EMA review for safety and efficacy.
• Regulatory agencies stress that compounded semaglutide should stay limited to periods of verified shortage.

Limitations

The data rest mostly on voluntary adverse event reports. Those systems likely undercount total incidents. No head-to-head randomized trials compare compounded semaglutide directly with approved versions. Shortage status and compounding rules shift often. Anyone checking must consult the current FDA database. The information does not address long-term outcomes or compounding practices in every country.

FAQ

What specific adverse events has the FDA linked to compounded semaglutide?
Reports cite nausea, vomiting, diarrhea, dehydration, abdominal pain, pancreatitis and gallbladder issues. Some led to hospitalization.

Under what conditions does the FDA permit compounding of semaglutide?
Compounding is allowed only while the drug appears on the shortage list. It must occur under section 503A or 503B rules in compliant facilities.

How can patients and providers distinguish FDA-approved semaglutide from compounded or counterfeit versions?
Approved products come through legitimate pharmacies that dispense FDA-cleared formulations. Compounded versions often use unapproved salt forms and lack the same labeling and review.